ACTIVE_NOT_RECRUITING

Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a national-level research study of neurologists and dementia specialists. The purpose of this study is to assess the clinical evaluation and management recommendations made by practicing providers for patient simulations with symptoms of cognitive decline.

Official Title

Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay: A QURE Virtual Patient Randomized Controlled Trial

Quick Facts

Study Start:2025-08-08
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT07099001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Board-certified in neurology for at least two years (and no more than 35 years
  2. * Average at least 20 hours per week of clinical and patient care duties over the past six months
  3. * Routinely evaluate patients at risk for Alzheimer's disease
  4. * Practicing in the United States
  5. * Able to read English
  6. * Access to the internet
  7. * Not participating in a clinical research study of the AD assay
  8. * Informed, signed, and voluntarily consented to participate in this study
  1. * Board-certified in neurology for less than two years
  2. * Board certification in neurology over 35 years ago
  3. * Unable to read English
  4. * Unable to access the internet
  5. * Not practicing in the United States
  6. * Not averaging at least 20 hours per week of clinical or patient care duties over the past six months
  7. * Participating in a clinical research study of the AD assay
  8. * Do not voluntarily consent to participate in this study

Contacts and Locations

Principal Investigator

Trever Burgon, PhD
PRINCIPAL_INVESTIGATOR
QURE Healthcare

Study Locations (Sites)

QURE Healthcare
St Louis, Missouri, 63110
United States

Collaborators and Investigators

Sponsor: Qure Healthcare, LLC

  • Trever Burgon, PhD, PRINCIPAL_INVESTIGATOR, QURE Healthcare

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-08
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2025-08-08
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Patient Simulation

Additional Relevant MeSH Terms

  • Alzheimer Disease (AD)
  • Cognitive Decline